Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $442 | $65,149 | $65,857 | $70,333 |
| % Growth | -99.3% | -1.1% | -6.4% | – |
| Cost of Goods Sold | $283 | $41,474 | $41,872 | $44,503 |
| Gross Profit | $159 | $23,675 | $23,985 | $25,830 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $124 | $18,468 | $18,354 | $18,732 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $1,000 | -$1,000 |
| Operating Expenses | $124 | $18,469 | $19,354 | $17,732 |
| Operating Income | $35 | $5,206 | $4,631 | $8,098 |
| % Margin | 8% | 8% | 7% | 11.5% |
| Other Income/Exp. Net | $19 | -$1,246 | -$133 | $3,434 |
| Pre-Tax Income | $54 | $3,960 | $4,498 | $11,532 |
| Tax Expense | $16 | $1,447 | $136 | $3,463 |
| Net Income | $39 | $2,513 | $4,362 | $8,069 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS | 0.78 | 51.05 | 88.61 | 163.92 |
| % Growth | -98.5% | -42.4% | -45.9% | – |
| EPS Diluted | 0.78 | 51.05 | 88.61 | 163.92 |
| Weighted Avg Shares Out | 49 | 49 | 49 | 49 |
| Weighted Avg Shares Out Dil | 49 | 49 | 49 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $4 | $473 | $410 | $332 |
| Depreciation & Amortization | $38 | $5,249 | $5,337 | $5,162 |
| EBITDA | $96 | $10,456 | $10,968 | $12,260 |
| % Margin | 21.8% | 16% | 16.7% | 17.4% |